Clinical Trial

TIL Therapy in cSCC and MCC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this research study is to test the safety and effectiveness of a tumor-infiltrating lymphocyte (TIL) cellular therapy, also called LN-145 or lifileucel, and chemotherapy in combination with Interleukin-2 (IL-2) to find out what effects, if any, the combination has on participants with Cutaneous squamous cell carcinoma (CSCC) or Merkel Cell Carcinoma (MCC) who were previously treated with immunotherapy. The names of the study interventions involved in this study are: * Tumor Infiltrating Lymphocytes (a type of cellular therapy) * Fludarabine and Cyclophosphamide (types of standard of care chemotherapy drugs) * Interleukin-2 (a type of recombinant, human glycoprotein)
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-15.
Status change: Not Yet Recruiting → Recruiting 2026-02-11
Trial Details
NCT Number NCT07288073
Lead Sponsor Karam Khaddour, MD, MS
Collaborators: Iovance Biotherapeutics, Inc.
Conditions Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma, Skin Cancer
Enrollment 14 participants
Start Date 2026-02-10
Primary Completion 2028-09-29 (estimated)
Study Completion 2029-06-29 (estimated)
Updated on ClinicalTrials.gov 2026-02-13